PTP1B: A new therapeutic target for Rett syndrome

8Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

Abstract

Rett syndrome (RTT) is an X-linked neurodevelopmental disorder that is characterized by successive loss of acquired cognitive, social, and motor skills and development of autistic behavior. RTT affects approximately 1 in 10,000 live female births and is the second most common cause of severe mental retardation in females, after Down syndrome. Currently, there is no cure or effective therapy for RTT. Approved treatment regimens are presently limited to supportive management of specific physical and mental disabilities. In this issue, Krishnan and colleagues reveal that the protein tyrosine phosphatase PTP1B is upregulated in patients with RTT and in murine models and provide strong evidence that targeting PTP1B has potential as a viable therapeutic strategy for the treatment of RTT.

Cite

CITATION STYLE

APA

Tautz, L. (2015, August 3). PTP1B: A new therapeutic target for Rett syndrome. Journal of Clinical Investigation. American Society for Clinical Investigation. https://doi.org/10.1172/JCI83192

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free